DECLOMYCIN (demeclocycline hydrochloride) by Pfizer is clinical pharmacology pharmacokinetics the absorption of demeclocycline is slower than that of tetracycline. Approved for infections caused by the following gram-negative microorganisms, bacteriologic testing indicates appropriate susceptibility to the drug: escherichia coli, infections caused by the following gram-positive microorganisms and 7 more indications. First approved in 1964.
Drug data last refreshed 7h ago · AI intelligence enriched 6d ago
DECLOMYCIN (demeclocycline hydrochloride) is an oral tetracycline antibiotic approved in 1964 that treats infections caused by susceptible gram-positive and gram-negative bacteria, including rickettsial infections such as Rocky Mountain spotted fever and Q fever. It works by inhibiting bacterial protein synthesis, making it bacteriostatic. The drug has slower absorption than tetracycline with a serum half-life of 10–16 hours and reduced renal clearance compared to other tetracyclines.
Product is approaching loss of exclusivity with modest competitive pressure (30%), signaling a consolidating team and transition toward generic defense strategies.
CLINICAL PHARMACOLOGY Pharmacokinetics The absorption of demeclocycline is slower than that of tetracycline. The time to reach the peak concentration is about 4 hours. After a 150 mg oral dose of demeclocycline tablet, the mean concentrations at 1 hour and 3 hours are 0.46 and 1.22 mcg/mL (n = 6),…
Worked on DECLOMYCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on DECLOMYCIN offers career stability in a legacy brand role focused on operational excellence and generic transition management rather than growth or innovation. Positions typically emphasize cost control, market access, and stakeholder management in a declining-revenue environment.